
News|Articles|July 9, 2007
Latebreakers: Once daily PAH drug OK'd
Ambrisentan (Letairis) in 5-and 10-mg tablets has been approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Pneumococcal Vaccination at 50 Years Old Can Improve Outcomes
5





























































